Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Fibrates but not statins increase plasma selenium in dyslipidemic aged patients--the EVA study.

Arnaud J, Akbaraly TN, Hininger-Favier I, Berr C, Roussel AM.

J Trace Elem Med Biol. 2009;23(1):21-8. doi: 10.1016/j.jtemb.2008.08.001. Epub 2008 Oct 10.

PMID:
19203713
[PubMed - indexed for MEDLINE]
2.

Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.

Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.

Eur J Intern Med. 2009 Mar;20(2):197-200. doi: 10.1016/j.ejim.2008.06.009. Epub 2008 Aug 15.

PMID:
19327612
[PubMed - indexed for MEDLINE]
3.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
[PubMed - indexed for MEDLINE]
4.

The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.

Devroey D, Velkeniers B, Duquet W, Betz W.

Int J Cardiol. 2005 May 25;101(2):231-5.

PMID:
15882669
[PubMed - indexed for MEDLINE]
5.

Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.

Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, Jünger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ; DYSIS Investigators.

Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545. Epub 2011 Mar 10.

PMID:
21450578
[PubMed - indexed for MEDLINE]
6.

Combination therapy of statins and fibrates in the management of cardiovascular risk.

Fiévet C, Staels B.

Curr Opin Lipidol. 2009 Dec;20(6):505-11. doi: 10.1097/MOL.0b013e328332e9ef. Review.

PMID:
19829109
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.

Devroey D, Velkeniers B, Duquet W, Betz W.

Acta Cardiol. 2003 Jun;58(3):179-84.

PMID:
12846506
[PubMed - indexed for MEDLINE]
8.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
[PubMed - indexed for MEDLINE]
Free Article
9.

Significant increase in high-density lipoprotein cholesterol with fibrates is associated with low pretreatment high-density lipoprotein cholesterol: findings from an outpatient clinic setting.

Ramachandran S, Abbas A, Saraf S, Raju J, Jewkes C, Jones AF.

Metab Syndr Relat Disord. 2012 Jun;10(3):189-94. doi: 10.1089/met.2011.0112. Epub 2012 Jan 27.

PMID:
22283634
[PubMed - indexed for MEDLINE]
10.

Differential associations of statin and fibrate treatment with carotid arterial remodeling.

Chironi G, Simon A, Gariepy J, Balice M, Del-Pino M, Levenson J.

Am J Hypertens. 2005 Nov;18(11):1476-81.

PMID:
16280285
[PubMed - indexed for MEDLINE]
11.

Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.

Visnegarwala F, Maldonado M, Sajja P, Minihan JL, Rodriguez-Barradas MC, Ong O, Lahart CJ, Hasan MQ, Balasubramanyam A, White AC Jr.

J Infect. 2004 Nov;49(4):283-90.

PMID:
15474625
[PubMed - indexed for MEDLINE]
12.

'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.

Jacobson TA.

Int J Clin Pract. 2011 Jan;65(1):82-101. doi: 10.1111/j.1742-1241.2010.02547.x. Epub 2010 Nov 24. Review.

PMID:
21105969
[PubMed - indexed for MEDLINE]
13.

Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.

Nakajima K.

Curr Clin Pharmacol. 2010 May;5(2):133-9. Review.

PMID:
20156152
[PubMed - indexed for MEDLINE]
14.

Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.

Brautbar A, Covarrubias D, Belmont J, Lara-Garduno F, Virani SS, Jones PH, Leal SM, Ballantyne CM.

Atherosclerosis. 2011 Dec;219(2):737-42. doi: 10.1016/j.atherosclerosis.2011.08.015. Epub 2011 Aug 22.

PMID:
21889769
[PubMed - indexed for MEDLINE]
15.

[Becoming more "goal-oriented" in therapy of dyslipidemias: results of the Hungarian MULTI GAP 2010].

Reiber I, Paragh G, Márk L, Pados G.

Orv Hetil. 2011 May 22;152(21):822-7. doi: 10.1556/OH.2011.29127. Hungarian.

PMID:
21546340
[PubMed - indexed for MEDLINE]
16.

Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.

Goldberg AC, Bittner V, Pepine CJ, Kelly MT, Thakker K, Setze CM, Lele A, Sleep DJ.

Am J Cardiol. 2011 Mar 15;107(6):898-905. doi: 10.1016/j.amjcard.2010.11.009. Epub 2011 Jan 19.

PMID:
21247520
[PubMed - indexed for MEDLINE]
17.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
[PubMed - indexed for MEDLINE]
18.

The treatment of dyslipidemia--what's left in the pipeline?

Rau O, Zettl H, Popescu L, Steinhilber D, Schubert-Zsilavecz M.

ChemMedChem. 2008 Feb;3(2):206-21. Review.

PMID:
17963209
[PubMed - indexed for MEDLINE]
19.

[Treatment of dyslipidemia: how and when to combine lipid lowering drugs].

Schulz I.

Arq Bras Endocrinol Metabol. 2006 Apr;50(2):344-59. Epub 2006 May 23. Review. Portuguese.

PMID:
16767301
[PubMed - indexed for MEDLINE]
Free Article
20.

Pitavastatin: clinical effects from the LIVES Study.

Teramoto T.

Atheroscler Suppl. 2011 Nov;12(3):285-8. doi: 10.1016/S1567-5688(11)70888-1. Review.

PMID:
22152283
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk